undamentalytics Newsletter
Sign in

Allogene Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Allogene Therapeutics, Inc. had total assets of $416m, total liabilities of $123m and shareholders' equity of $293m. It held $51.7m in cash against $0 of debt: net cash of $51.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents17518317362837552
Total current assets545845471529459303258
Total assets7181,2281,051822643549416
Accounts payable9101014654
Deferred revenue (current)039000——
Total current liabilities33944854373633
Total debt0000000
Total liabilities89148126155131127123
Shareholders' equity6291,013925667512422293
Non-controlling interests and other (assets − liabilities − equity)—66—————
Net debt (negative = net cash)−175−183−173−62−83−75−52
Shares outstanding124m140m143m144m169m212m229m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allogene Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allogene Therapeutics, Inc.